Page 105 - Sohini Das

Alembic Pharma forms JV to enter a difficult $100 bn Chinese market

Alembic hold 44% in partnership with China's SPH SINE Pharma, whose stake will be 51%. The JV will set up plant there

Bulk drug exports rise as Indian makers cash in on China's regulatory woes

Iran emerged as a major destination in FY19 with 68% growth after registering negative growth in FY17 and FY18

We have big expectations from Japan and China: Sun Pharma's Dilip Shanghvi

Shangvi feels the domestic market is big enough to accommodate both branded and unbranded medicines

Foreign investors have good appetite for InvITs, says India Inc

Sebi had reduced the minimum subscription limit for InvITs from Rs 10 lakh to Rs 1 lakh last month & raised the leverage limit from 49% to 70%

Political coalition fine, but should work towards progress: India Inc

Adi Godrej felt that the government needed to pay a lot of attention to economic and social development

Dr Reddy's Laboratories renews focus on chronic segment; gets India head

The pharma major is on a restructuring drive

Synergy will bring in Rs 6,200 crore, Vodafone Idea says in capex plan

The capital push comes from a strong need to match rivals on the 4G subscriber base

Local pharma companies to challenge MNCs in pneumonia vaccine space

The Indian market is at present dominated by GlaxoSmithKline Pharma and Pfizer

With RCom deal terminated, Jio is ready to buy spectrum from open market

Anshuman Thakur, head of strategy and planning at Jio, said during the fourth quarter results press conference that it was open to buying more spectrum if required

Reliance Retail's strong run continues, revenue crosses Rs 1.3 tn in FY19

The company operates 10,415 stores in over 6,600 cities, covering an area of over 22 million sq ft as on March 31, 2019

Reliance Jio Q4 net profit rises 65% to Rs 840 crore; revenues up 55%

The subscriber base crossed 300 million with a net addition of 26.6 million during the quarter

Fortis Healthcare remains a critical asset for IHH's global plans

Malaysian firm building team in Fortis even as there is status quo on the deal

Centre may get stricter to check overcharging of medicines by pharma cos

The idea is to cancel the licenses of manufacturers who do not deposit the demanded amount within the prescribed time limit given by the NPPA

Telcos operating under stress as adjusted gross revenue down by 6.4%

Telcos pay SUC and licence fees to the DoT on the basis of their AGR

Finally, Indian pharmaceutical industry scores on compliance with USFDA

2018 saw remedial work finally bearing fruit

Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market

Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs

Vodafone Idea board approves Rs 25,000 crore rights issue at 60% discount

Discount of 33% to post-issue adjusted price, 60% to current price

Domestic stent market on a healthy growth track despite price controls

According to industry estimates in 2018 calendar year the overall Indian cardiac stent market grew by 16-18 per cent in terms of volumes

RCom, Reliance Jio terminate agreement for sale of telecom assets

RCom has cited delays in approval from the government and lenders as the reason

Novartis, Gilead veteran named Glenmark's innovative business CEO

Riva's appointment as CEO of Glenmark's innovation business is effective from April 2.